Log In Sign up
The largest database of trusted experimental protocols

Ruxolitinib rux

Manufactured by Chemietek
Visit Supplier

Ruxolitinib (Rux) is a selective Janus kinase (JAK) inhibitor. It is a white to off-white crystalline powder.

Automatically generated - may contain errors

Lab products found in correlation

Anti mouse cd4 antibody, by BioXCell (2 mentions) Rat igg, by Merck Group (2 mentions) Ambisome, by Chemietek (2 mentions)

2 protocols using ruxolitinib rux

1

Modulation of Immune Responses in Leishmaniasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ T cells were selectively depleted with 0.5 mg anti-mouse CD4 antibody (clone: GK1.5; BioXCell) administered via intraperitoneal injection every 3 days over a two week period (Bunn et al., 2014 (link)). Similarly, neutralization of type I IFN and IFNγ signaling was achieved via administration of 0.1 mg purified anti-mouse IFNAR-1 antibody (clone: MAR1-5A3; Haque et al., 2014 (link)) or 0.5 mg anti-mouse IFNγ (clone: XMG1.2; Haque et al., 2011 (link)), respectively, every 3 days over a two week period. Control mice received an equivalent amount of rat IgG (Sigma-Aldrich). For anti-parasitic drug treatment experiments, mice were infected for 14 days with L. donovani before being treated with either a single, low dose of AmBisome (Amblo; 1 mg/kg) or a single, high dose of AmBisome (Ambhi; 10 mg/kg) i.v.. Some mice received 60 mg/kg ruxolitinib (Rux; ChemieTek) orally, twice daily for 5 days, based on dosing used in mice by others (Bhagwat et al., 2014 (link); Xing et al., 2014 (link)), or the same volume (200 μl) of vehicle (DMAc; Sigma-Aldrich).
Kumar R., Bunn P.T., Singh S.S., Ng S.S., de Oca M.M., De Labastida Rivera F., Chauhan S.B., Singh N., Faleiro R.J., Edwards C.L., Frame T.C., Sheel M., Austin R.J., Lane S.W., Bald T., Smyth M.J., Hill G.R., Best S.E., Haque A., Corvino D., Waddell N., Koufariotis L., Mukhopadhay P., Rai M., Chakravarty J., Singh O.P., Sacks D., Nylen S., Uzonna J., Sundar S, & Engwerda C.R. (2020). Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Cell reports, 30(8), 2512-2525.e9.
+ Open protocol
+ Expand
2

Modulation of Immune Responses in Leishmaniasis

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ T cells were selectively depleted with 0.5 mg anti-mouse CD4 antibody (clone: GK1.5; BioXCell) administered via intraperitoneal injection every 3 days over a two week period (Bunn et al., 2014 (link)). Similarly, neutralization of type I IFN and IFNγ signaling was achieved via administration of 0.1 mg purified anti-mouse IFNAR-1 antibody (clone: MAR1-5A3; Haque et al., 2014 (link)) or 0.5 mg anti-mouse IFNγ (clone: XMG1.2; Haque et al., 2011 (link)), respectively, every 3 days over a two week period. Control mice received an equivalent amount of rat IgG (Sigma-Aldrich). For anti-parasitic drug treatment experiments, mice were infected for 14 days with L. donovani before being treated with either a single, low dose of AmBisome (Amblo; 1 mg/kg) or a single, high dose of AmBisome (Ambhi; 10 mg/kg) i.v.. Some mice received 60 mg/kg ruxolitinib (Rux; ChemieTek) orally, twice daily for 5 days, based on dosing used in mice by others (Bhagwat et al., 2014 (link); Xing et al., 2014 (link)), or the same volume (200 μl) of vehicle (DMAc; Sigma-Aldrich).
Kumar R., Bunn P.T., Singh S.S., Ng S.S., de Oca M.M., De Labastida Rivera F., Chauhan S.B., Singh N., Faleiro R.J., Edwards C.L., Frame T.C., Sheel M., Austin R.J., Lane S.W., Bald T., Smyth M.J., Hill G.R., Best S.E., Haque A., Corvino D., Waddell N., Koufariotis L., Mukhopadhay P., Rai M., Chakravarty J., Singh O.P., Sacks D., Nylen S., Uzonna J., Sundar S, & Engwerda C.R. (2020). Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Cell reports, 30(8), 2512-2525.e9.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!